Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. Issue 4 (December 2018)

• Record Type: Journal Article
• Authors: Appelbaum, Frederick R.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 31:Issue 4(2018)
• Page Start: 405
• Page End: 409
• Publication Date: 2018-12
• Subjects: Acute myeloid leukemia -- AML -- Core binding factor -- Hematopoietic cell transplantation -- HCT -- Measurable residual disease -- MFC -- MRD -- Multi-parameter flow cytometry -- Next generation sequencing -- NGS -- NPM1 -- Reverse transcriptase polymerase chain reaction -- RT-PCR; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2018.09.009
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: The persistence of measurable residual disease (MRD) following induction chemotherapy is the single most powerful prognostic factor available to clinicians treating patients with acute myeloid leukemia (AML). How to use this information to guide subsequent therapy is complex, and influenced by the category of AML being treated, the assays used to measure MRD, MRD levels and kinetics, and the spectrum of therapies available to the patient. In this literature-based review, each of these issues will be discussed, with a particular emphasis on the role of hematopoietic cell transplantation in the treatment of MRD-positive patients.